Microwave ablation plus chemotherapy significantly improves progression-free survival in advanced NSCLC without increasing toxicity compared to chemotherapy alone. The combination treatment leverages ...

Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...

Investigators evaluated the efficacy and safety of toripalimab versus dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.

In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable ...

Investigators sought to determine if zanidatamab and chemotherapy, with or without tislelizumab, could extend PFS and OS in patients with untreated locally advanced or metastatic gastroesophageal ...

Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) significantly ...

Please provide your email address to receive an email when new articles are posted on . Results showed longer median PFS and a higher 9-month PFS with ivonescimab than pembrolizumab. Patients with ...

Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...

– In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups – – Although median overall ...

Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data from investigational BTK ...

(BUSINESS WIRE )--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by ...